IL17A and inflammatory bowel disease: Case reports of IBD in psoriasis patients receiving ixekizumab, a second IL-17A antibody, have been reported (Philipose et al., 2018; Smith et al., 2019), although post hoc analyses of ixekizumab trials suggest that IBD is a rare adverse outcome (Reich et al., 2017).